Detalhe da pesquisa
1.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet
; 393(10167): 143-155, 2019 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30420123
2.
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests.
Expert Opin Drug Saf
; 23(4): 527-537, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38482670
3.
A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.
Expert Opin Drug Saf
; 23(4): 477-486, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38469902
4.
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.
Drug Saf
; 47(4): 321-332, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38353882
5.
Psychiatric Symptoms in Patients Receiving Dolutegravir.
J Acquir Immune Defic Syndr
; 74(4): 423-431, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27984559